YIYuliya Sergeevna Ignatova

Yuliya Sergeevna Ignatova

*This is an algorithmically generated author record based on publicly available information.

Yuliya Sergeevna Ignatova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Potential of sodium-glucose cotransporter 2 inhibitors in donor heart recipients. A literature review

    by Yu. S. Ignatova, D. N. Shaputko, T. B. Pechorina, O. L. Barbarash

    Despite the emergence of new classes of medications for heart failure (HF), the global prevalence of HF continues to grow. Over the past decades, the number of heart transplants as a radical treatment for end-stage HF has increased significantly. A new class of drugs, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, have demonstrated efficacy in reducing cardiovascular mortality in patients with HF. It is of interest to study these drugs in donor heart recipients for their impact on cardiovascular risk and complications after orthotopic heart transplantation (OHT). This review presents the results of limited studies of SGLT-2 inhibitors in donor heart recipients with type 2 diabetes and prediabetes, as solid organ transplant recipients were excluded from most clinical trials, including due to adverse events. SGLT-2 inhibitors (empagliflozin and dapagliflozin) have de­monstrated safety and the ability to manage cardiovascular risk in patients after OHT. However, further study of this group of drugs is required, focusing on the prevention of complications after OHT.

  • Open Access

    Challenges in managing adherence in patients with cardiovascular disease (review)

    by Yu. S. Ignatova, Ya. I. Bryukhanov, T. B. Pecherina, O. L. Barbarash, Я. И. Брюханов

    Cardiovascular diseases (CVD) remain one of the main problems in most countries of the modern world. In this connection, maintaining adherence to the treatment and prevention of CVD is a priority in the fight against diseases of the cardiovascular system. According to the WHO, insufficient adherence to treatment is an urgent medical problem. Approximately 35 % of patients cancel taking medications within a year after an acute cardiovascular event, which leads to a threefold increase in the risk of complications. The purpose of the review is to highlight the problem of low adherence in the aspect of CVD and highlight the main methods of increasing adherence to treatment. This article reflects the main aspects of adherence management, considers the factors leading to a decrease in the level of disease control, identifies the causes of low adherence, and identifies methods for increasing adherence to treatment in patients with CVD.


  • Open Access

    Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure

    by Yu. S. Ignatova, S. U. Shuster, T. B. Pecherina, O. L. Barbarash

    Heart failure (HF) is an urgent public health problem worldwide. A fundamental role in HF progression is played by fibrosis, which causes structural myocardial and vascular changes. In this regard, it seems relevant to search for pathogenetically justified HF therapy, aimed at slowing the myocardial fibrosis progression. The results of EMPA-REG OUTCOME study showed that glucose-lowering drugs, namely sodium-glucose cotransporter 2 (SGLT2) inhibitors, have a positive effect on HF course, reducing cardiovascular mortality and hospitalization rate of patients for decompensated HF. Large-scale studies showed the antifibrotic properties of SGLT2 inhibitors. The review article presents the results of experimental studies on the use of SGLT2 inhibitors in animals. A number of mechanisms for the implementation of the antifibrotic properties of SGLT2 inhibitors affecting the cardiovascular system have been described. It seems relevant to further study SGLT2 inhibitors in clinical trials in order to identify and correct the pathogenetic mechanisms of myocardial fibrosis.


  • Open Access

    Visceral adiposity index in patients with coronary artery disease, obesity and type 2 diabetes

    by A. A. Khorlampenko, V. N. Karetnikova, A. M. Kochergina, Yu. S. Ignatova, E. V. Belik, O. V. Gruzdeva, Н. К. Брель, A. N. Kokov, O. L. Barbarash

    Aim. To assess visceral adiposity index (VAI) in patients with coronary artery disease (CAD) and overweight or obesity, as well as to determine its relationship with lipid and carbohydrate metabolism parameters and inflammatory markers, depending on the presence of carbohydrate metabolism disorders (CMD).Material and methods. The study included 95 patients with CAD and overweight (body mass index (BMI) >25 kg/m2) or obesity (BMI >30 kg/m2), of which 59 patients had type 2 diabetes (T2D) and 36 were without CMD. All patients were assessed for obesity; VAI was calculated. Following laboratory parameters were evaluated: glucose, glycated hemoglobin, C-reactive protein, adiponectin, lipid panel. In patients without history of CMD, an oral glucose tolerance test was performed.Results. Compared with patients without CMD, subjects with T2D had significantly higher values of BMI, waist circumference, as well as the body fat percentage, area and volume of visceral adipose tissue estimated by computed tomography. Analysis of lipid profile, C-reactive protein and adiponectin levels did not reveal significant differences between the groups. VAI also did not significantly differ in both groups. VAI had the most correlations with clinical and metabolic parameters in both patients with T2D and without CMD. Other methods for assessing obesity were less correlated with laboratory parameters in both groups. Only VAI significantly correlated with adiponectin in both groups.Conclusion. The obtained correlations between VAI and clinical and metabolic parameters confirm the practicability of using it to determine adipose tissue dysfunction in patients with/without CMD. The effect of increased VAI on the cardiovascular risk in high-risk patients requires further study.


  • Effect of empagliflosin on renal filtration in patients with coronary heart disease undergoing percutaneous coronary intervention

    by A. A. Khorlampenko, V. N. Karetnikova, A. M. Kochergina, J. S. Ignatova, J. A. Dyleva, O. V. Gruzdeva, O. L. Barbarash

    Aim To evaluate the effect of empagliflozin on glycemia and renal filtration function in patients with stable ischemic heart disease (IHD) and type 2 diabetes mellitus (DM2) who underwent a percutaneous coronary intervention (PCI). Materials and methods This study included 40 patients with stable IHD and DM2 (age, 63 (58; 65) years; DM2 duration, 7 (4; 15) years) who had indications for an elective PCI. At baseline in the total sample, the level of glycated hemoglobin was 7.2 (6.5; 8.3)%; 48.7 % failed to achieve glycemic goals. A decrease in glomerular filtration rate (GFR) to below 60 ml/min/1.73 m2 was observed in 10.3 % of patients. All patients were divided into two group by simple randomization with successively assigned numbers. The main group consisted of 20 patients who received empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy irrespective of their baseline glycemic control. Patients of the comparison group (n=20) continued on their previous hypoglycemic therapy as prescribed by their endocrinologist. The follow-up duration was 6 months. Statistical analysis was performed with the Statistica 10.0 software. Results The empagliflozin treatment improved the glycemic control; in the comparison group, no significant changes in glycemic control were observed. In both groups, GFR significantly decreased during the follow-up period; median decreases in GFR were –6.0 (–16.0; 4.0) and –8.4 (–26.5; 2.5) ml/min / 1.73 m2 in the main and comparison groups, respectively (p = 0.646). No significant changes in 24-h proteinuria were observed for patients taking empagliflozin. In the control group, the 24-h urinary protein excretion significantly progressed (p=0.011) during the follow-up period. Conclusion In patients with DM2 and stable IHD who underwent a PCI, addition of empagliflozin 10 mg/day to their current hypoglycemic therapy was associated with a significant improvement of glycemic control. The decrease in GFR during the empagliflozin treatment did not significantly differ from the value for patient receiving the other hypoglycemic therapy.


  • Open Access

    Outcomes of long-term observation period in patients with myocardial infarction undergone radiopaque interventions in the acute period of the disease.

    by V. N. Karetnikova, V. V. Kalaeva, M. V. Evseeva, O. V. Gruzdeva, A. A. Shilov, Yu. S. Ignatova, O. L. Barbarash

    Introduction. Currently, the importance of various factors in the acute period of myocardial infarction (MI) for the risk stratification of unfavourable course ofpost-infarction period is continued to be studied. Purpose. We aimed to identify the factors, affecting the formation of adverse outcomes of in-hospital and long-term postinfarction period in patients with ST-elevated MI (STEMI) undergone radiopaque interventions (ROI). Material and methods. The study included 954 STEMI patients admitted to the Kemerovo Cardiology Dispensary in the period from 2008 to 2010. Diagnostic coronary angiography was performed in 725 (76%) patients, and 557 (76.8%) of cases undergone myocardial revascularization (isolated balloon angioplasty, angioplasty with stenting). Results. The in-hospital mortality in STEMI patients was associated with the age older than 60 years (OR 2.4 95% CI 1.4-3.9, p60 years), 4.1-fold in development of CIN (OR 4.1 95% CI 1.1-14.3). The area under the ROC-curve was 0.744 (0.632-0.856, р=0.001). Conclusion. The independent risk factors of fatal outcome development within the in-hospital period in STEMI patients undergone ROI were: the age older than 60years, LVEF reduce less than 40% and the presence of CIN. Fatal outcomes within a year after MI were associated with GFR decrease less than 60 ml/min/1.73 m, LVEF less than 40% and CIN development, and within three years - AHF Killip class II and greater, age older than 60 years, as well as CIN after ROI.